2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. 1998

A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
Brain Imaging Center, Intramural Research Program, National Institute on Drug Abuse, 5500 Nathan Shock Drive, Baltimore, Maryland 21224, USA. akoren@intra.nida.nih.gov

3-(2(S)-Azetidinylmethoxy)pyridine (A-85380) has been identified recently as a ligand with high affinity for nicotinic acetylcholine receptors (nAChRs). Here we report the synthesis and in vitro nAChR binding of a series of 10 pyridine-modified analogues of A-85380. The novel compounds feature a halogen substituent at position 2, 5, or 6 of the 3-pyridyl fragment. Those with the substituents at position 5 or 6, as well as the 2-fluoro analogue, possess subnanomolar affinity for nAChRs in membranes from rat brain. For these ligands, Ki values range from 11 to 210 pM, as measured by competition with (+/-)-[3H]epibatidine. In contrast, 2-chloro, 2-bromo, and 2-iodo analogues exhibit substantially lower affinity. AM1 quantum chemical calculations demonstrate that the bulky substituents at position 2 cause notable changes in the molecular geometry. The high-affinity members of the series and (+)-epibatidine display a tight fit superposition of low-energy stable conformers. The new ligands with high affinity for nAChRs may be of interest as pharmacological probes, potential medications, and candidates for developing radiohalogenated tracers to study nAChRs.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001384 Azetidines
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
May 2000, Nuclear medicine and biology,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
May 2002, Annals of nuclear medicine,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
June 1999, Journal of medicinal chemistry,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
January 1998, Life sciences,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
June 1996, Neuropharmacology,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
November 2011, Nuclear medicine and biology,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
January 2001, Nuclear medicine and biology,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
January 1999, Life sciences,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
November 2001, Bioorganic & medicinal chemistry,
A O Koren, and A G Horti, and A G Mukhin, and D Gündisch, and A S Kimes, and R F Dannals, and E D London
May 1998, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!